UVA1 Phototherapy for LS: What Actually Happens in Practice
UVA1 phototherapy is one of the newer options on the table when first-line treatments stop working. The standard prescription involves narrowband UVA lamps operating between 340 and 400 nanometers, typically at irradiance levels of 100 to 300 mW/cm² depending on the device. Patients usually start with lower doses around 5 to 10 Joules per square centimeter and build up over two to three weeks to a therapeutic range of 40 to 60 J/cm² delivered in sessions lasting ten to twenty minutes each. The treatment happens three times per week, and a full course runs roughly eight to twelve weeks before you can judge whether it's working. UVA1 penetrates deeper into the reticular dermis than standard UVB, which matters because lichen sclerosus pathology sits deep in the tissue. The mechanism involves modulation of immune cell activity, reduction of inflammatory cytokines, and some impact on fibroblast function that may help soften hardened skin over time. It doesn't reverse established sclerosis completely, but several studies have shown meaningful symptom reduction in approximately 60 to 70 percent of patients who complete a full course. This includes improvements in itching, pain, and pliability of the affected tissue. I found that the real practical challenge is setting expectations. UVA1 is not a cure. It's a disease-modifying treatment that buys you a window of relief, and when you stop the sessions, symptoms tend to creep back over months. Some patients need occasional maintenance sessions just to stay ahead of it. Another thing nobody tells you upfront is that the lights are intense enough that you need protective eyewear rated for UVA, and bare skin outside the treatment area needs coverage. Genital and perianal treatment requires careful positioning that most home units don't accommodate well, which is why clinic-based phototherapy often makes more sense for extensive involvement.
Practical Considerations That Come Up After the First Few Weeks
Dose escalation needs to be methodical. The starting dose is calculated based on your minimal erythema dose from a test session, though some clinics skip that step and use fixed starting doses based on skin type. If you're doing home phototherapy, the biggest mistake people make is pushing the dose too aggressively. A mild pinkness twenty-four hours after treatment is normal. You're aiming for that low-level erythema as a sign the dose is working, not burning. If you get a painful burn, you set the whole course back by a week or more. The equipment question is worth addressing honestly. Clinic-based units deliver higher, more consistent irradiance and cover larger areas evenly. Home units are significantly cheaper in the long run but have lower output and narrower coverage zones. For limited genital LS, a home unit can work fine. For more widespread involvement, the uneven coverage becomes a real problem. I encountered a specific issue with one patient whose home unit had a hot spot in the center of the panel that caused a localized burn despite her following the protocol exactly. The fix was having the device serviced and replacing the lamp array, but the underlying lesson is that home units degrade over time and their output isn't always what the dial says it is. Cheap units in particular can drift significantly from their stated irradiance within months. Skin darkening is common during a treatment course. This isn't tanning in the cosmetic sense—it's a physiological response to repeated UVA exposure. It fades slowly after treatment ends, but it can take several months. More importantly, UVA exposure accelerates photoaging, and while the doses used in LS treatment are controlled and limited, there's still cumulative risk that matters if you're doing maintenance therapy for years. The theoretical cancer risk with UVA1 is still being studied, and the data isn't conclusive either way, but it's a factor to discuss with your dermatologist.
Who Should Skip This Route
If you have a history of photosensitivity disorders, certain autoimmune conditions like lupus, or previous skin cancers in the treatment area, UVA1 is probably not a good option. Same goes for anyone taking photosensitizing medications—common ones include certain antibiotics, diuretics, and some psychiatric medications. Check with your prescriber before starting. Topical calcineurin inhibitors like tacrolimus also increase photosensitivity, and combining them with UVA1 therapy without medical supervision is risky. There's also the time commitment to consider. Three sessions per week for two to three months isn't trivial. People who can't maintain that schedule often see poor results, not because the therapy doesn't work, but because inconsistent dosing undermines the whole treatment. If you're already struggling with daily topical steroid application, adding phototherapy on top of that is another layer of maintenance that might not be sustainable. The evidence base for UVA1 in LS is still growing. Most studies are small, and there's no universally agreed-upon protocol. Some dermatologists prefer combining it with topical steroids rather than using it as a standalone treatment. That combination approach tends to produce faster symptom relief, though it doesn't necessarily change the long-term outcome compared to either therapy alone.
Get the Full Details
If you're considering this route, the practical first step is getting a referral to a dermatology clinic with phototherapy capability. Bring a list of all your current medications and a clear description of what symptoms are driving your decision. They'll determine whether your particular presentation and medical history make you a suitable candidate, and if so, what starting dose they'd recommend based on your skin type and the extent of the disease.
